sample="quota" bates="507731404" isource="rjr" decade="Bliley" class="ni" date="19900831" FAX (816) 421-5647 W. U. T. TELEX 426291 SHC KSC A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS LAW OFFICES SHOOK, HARDY & BACON ONE KANSAS CITY PLACE 1200 MAIN STREET KANSAS CITY, MISSOURI 64105 (816) 474-6550 RECEIVED SEP 5 '90 WWJ OTHER OFFICES 40 CORPORATE WOODS OVERLAND PARK, KANSAS 19 BUCKINGHAM GATE LONDON, ENGLAND August 31, 1990 W- We have approved this in the past as a CTR Special Project. I have attached an app. letter for you and I have pulled the file if you need it. Wayne W. Juchatz, Esq. Josiah S. Murray, III, Esq. Ernest Pepples, Esq. Paul A. Randour, Esq. Arthur J. Stevens, Esq. Charles R. WAWll, Esq. Re: Feinstein Research Proposal Gentlemen: We have received a request from Dr. Alvan Feinstein for renewal of his research support from the tobacco industry . As indicated in the attached letter, Dr. Feinstein has received CTR support for the past four years and is now requesting continued funding. Also attached for your information are copies of several scientific articles that have been published during the time period of CTR support. By all accounts, Dr. Feinstein remains very active in the field of clinical epidemiology. His work is frequently cited and often generates scientific debate in both medical and epidemiological circles. Dr. Feinstein's recent research on the underdiangosis of lung cancer, based on autopsy data, is a good example. With regard to the requested funding, Dr. Feinstein will focus his activities on the following areas: (1) continued review of lung cancer statistics for accuracy; (2) examination of lung cancer staging data to track improvements in diagnosis; (3) review the relationship between cigarette smoking history and the age lung cancer develops along with the prognosis of the disease; and (4) performance of new studies in the areas of geographic and temporal distribution of lung cancer. Dr. Feinstein has requested continued research support in the amount of approximately $276,140.00 for the first year. He has estimated that the amount would be increased approximately 5% if the research were continued for a second and/or third year. Dr. Feinstein's estimates and the accompanying explanations are contained in his attached request. Given the relevance and high quality of Dr. Feinstein's past research, we recommend that his project be funded for one additional year with a possible extension depending on the progress of the work. We also propose that the research be funded directly by the companies on a market share basis (using the most recent Maxwell figures). Phillip Morris 43% $ 118,740.00 Reynolds 28.1% $ 77,595.00 Brown & Williamson 11.8% $ 32,585.00 Lorillard 7.5% $ 20, 711.00 American 6.5% $ 17,949.00 Liggett 3.1% $ 8,560.00 $276,140.00 Please let me know as soon as practicable whether your company will participate in the support of the Feinstein research. Cordially, Patrick M. Sirridge PMS/tks cc: Janet C. Brown, Esq. Francis K. Decker, Esq. Michael A. Nims, Esq.